3.1.12. follow-up transplantation. long-term graft function critical importance success transplant . therefore, regular long-term follow-up experienced transplant physicians essential order detect complications graft dysfunction early reassure adherence immunosuppressive regimen. complications immunosuppression occur frequently including specific complications different drugs well immunosuppression (namely opportunistic infections malignancy) . risk cancer cardiac disease several-fold higher transplanted patients general population. cancer cause significant morbidity mortality transplanted population . cardiovascular disease frequent cause death renal allograft recipients . important long-term problems non-adherence , development anti-hla antibodies, recurrence original disease cni associated nephrotoxicity . 3.1.12.1. chronic allograft dysfunction/interstitial fibrosis tubular atrophy many patients lose grafts due chronic allograft dysfunction . histology usually reveal chronic process interstitial fibrosis tubular atrophy (if/ta) . patients immunological chronic abmr , discussed section 3.1.11.3. interstitial fibrosis tubular atrophy takes months years develop heralded proteinuria hypertension, simultaneous delayed rise serum creatinine level months . likely if/ta common patients early attacks acute rejection infection. main differential diagnosis chronic nephrotoxicity , common patients receiving cnis, pre-existing and/or aggravated chronic kidney damage marginal donor kidney . diagnosis renal biopsy . patients diagnosed early, particularly evidence cni toxicity, disease progression may slowed conversion cni-free regimen [201-203,263,264]. conversion m-tor inhibitors option patients without significant proteinuria (< 800 mg/day), moderate renal function [243-245]. alternatively, successful conversion mycophenolate based regimen described, especially patients beyond first three years post-transplant . intolerance m-tor inhibitors mpa, conversion belatacept azathioprine-based regimen may successful, though higher risk rejection warrants close surveillance . risk rejection seems high, another option substantial reduction cni protection mpa . patients proteinuria, intervention angiotensin converting enzyme inhibitor, angiotensin ii receptor blocker together tight blood pressure control may slow renal progression. supportive measures include treatment hypertension, hyperlipidaemia, diabetes, anaemia, acidosis, bone disease . however, ultimately, patient require another transplant (if fit enough go transplant waiting list) dialysis therapy. summary evidenceleregular long-term follow-up experienced transplant physicians essential order detect complications graft dysfunction early reassure adherence immunosuppressive regimen.4annual screening include dermatological examination, cardiovascular history exam, tumour screening (including nodal examination, faecal occult screening, chest x-ray, gynaecological urological examination), abdominal us, including us native transplanted kidney. appropriate, diagnostic tests prompted treat slow progression identified complication.4in patients diagnosed early if/ta, particularly evidence cni toxicity, disease progression may slowed conversion cni-free regimen. risk rejection seems high, another option substantial reduction cni protection mpa.1supportive measures aim adequately treat consequences chronic kidney disease (e.g. anaemia, acidosis, bone disease).4 recommendationsstrength ratingprovide lifelong regular post-transplant follow-up experienced trained transplant specialist least every six twelve months.strongadvise patients appropriate lifestyle changes, potential complications, importance adherence immunosuppressive regimen.strongregularly monitor (approximately every four eight weeks) serum creatinine, estimated glomerular filtration rate, blood pressure, urinary protein excretion, immunosuppression complications renal transplantation. changes parameters time trigger diagnostic work-up including renal biopsy, search infectious causes anti-hla antibodies.strongperform ultrasound graft, case graft dysfunction, rule obstruction renal artery stenosis.strongin patients interstitial fibrosis tubular atrophy undergoing calcineurin inhibitor (cni) therapy and/or histological signs suggestive cni toxicity (e.g. arteriolar hyalinosis, striped fibrosis) consider cni reduction withdrawal.stronginitiate appropriate medical treatment, e.g. tight control hypertension, diabetes, proteinuria, cardiac risk factors, infections, complications according current guidelines.strong